Comparison of high-sensitivity C-reactive protein and fetuin-A levels before and after treatment for subjects with subclinical hyperthyroidism

Simple item page
dc.contributor.authorBilgir O.
dc.contributor.authorBilgir F.
dc.contributor.authorTopcuoglu T.
dc.contributor.authorCalan M.
dc.contributor.authorCalan O.
dc.date.accessioned2024-07-22T08:17:17Z
dc.date.available2024-07-22T08:17:17Z
dc.date.issued2014
dc.description.abstractThis study was designed to show the effect of propylthiouracil treatment on sCD40L, high-sensitivity C-reactive protein, and fetuin-A levels on subjects with subclinical hyperthyroidism. After checking sCD40L, high-sensitivity C-reactive protein, and fetuin-A levels of 35 patients with subclinical hyperthyroidism, each was given 50 mg tablets of propylthiouracil three times daily. After 3 months, sCD40L, high-sensitivity C-reactive protein, and fetuin-A levels were then compared to the levels before treatment. Although high-sensitivity C-reactive protein and sCD40L levels were normal in the subclinical hyperthyroidism patients compared to the healthy controls, fetuin-A levels were statistically significantly higher (*p = 0.022). After treatment, fetuin-A levels of subclinical hyperthyroidism patients decreased statistically significantly compared to the levels before treatment (**p = 0.026). sCD40L and high-sensitivity C-reactive protein levels did not have a statistically significant difference compared to the control group and post-propylthiouracil treatment. In subclinical hyperthyroidism patients, high fetuin-A levels before propylthiouracil treatment and decreases in these levels after treatment in cases with subclinical hyperthyroidism indicated the possibility of preventing long-term cardiac complications with propylthiouracil treatment. © 2013 Springer Science+Business Media New York.
dc.identifier.DOI-ID10.1007/s12020-013-9993-z
dc.identifier.issn1355008X
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/17019
dc.language.isoEnglish
dc.publisherHumana Press Inc.
dc.subjectAdult
dc.subjectalpha-2-HS-Glycoprotein
dc.subjectAntithyroid Agents
dc.subjectBiological Markers
dc.subjectC-Reactive Protein
dc.subjectCase-Control Studies
dc.subjectCD40 Ligand
dc.subjectDose-Response Relationship, Drug
dc.subjectFemale
dc.subjectHumans
dc.subjectHyperthyroidism
dc.subjectMale
dc.subjectPropylthiouracil
dc.subjectRetrospective Studies
dc.subjectTreatment Outcome
dc.subjectC reactive protein
dc.subjectCD40 ligand
dc.subjectfetuin A
dc.subjectliothyronine
dc.subjectpropylthiouracil
dc.subjectthyrotropin
dc.subjectthyroxine
dc.subjectadult
dc.subjectarticle
dc.subjectchemiluminescence analyzer
dc.subjectchemiluminescence immunoassay
dc.subjectclinical article
dc.subjectcontrolled study
dc.subjectELISA kit
dc.subjectenzyme linked immunosorbent assay
dc.subjectfemale
dc.subjecthuman
dc.subjectliothyronine blood level
dc.subjectmale
dc.subjectpriority journal
dc.subjectprotein blood level
dc.subjectsubclinical hyperthyroidism
dc.subjectsubclinical hypothyroidism
dc.subjectthyrotropin blood level
dc.subjectthyroxine blood level
dc.subjecttreatment duration
dc.subjecttreatment outcome
dc.titleComparison of high-sensitivity C-reactive protein and fetuin-A levels before and after treatment for subjects with subclinical hyperthyroidism
dc.typeArticle

Files

Collections

Scopus Koleksiyonu